We’ve always believed that dogs deserve the most advanced medical care possible. Today, we're excited to introduce Fetch™, our proprietary AI engine that is already transforming how we approach cancer treatment for dogs.
With 6 million new cases diagnosed annually in the United States alone, cancer is the leading cause of death for dogs. Cancer is a multifactorial and complex disease. For decades, the approach to treating canine cancer has been marked by limited options and a reliance on broad-spectrum treatments that often fail to account for the unique genetic profiles of individual cases. However, with our AI-driven precision medicine platform, we are positioned to shift the current canine cancer paradigm.
At FidoCure, we believe every dog deserves a chance to live their best life, even when faced with challenging diagnoses. The story of Romulus, a beloved Maremma guardian dog, is a testament to the power of personalized veterinary care.
For over nine years, Franklin has been a beloved member of the Noll-Mcclintock family—a funny, smart, and playful 8-year-old rescue dog. Two years ago, Franklin faced a challenging diagnosis: an incurable cancer originating in his spleen. Determined to give Franklin the best possible care, his mom Chelsea Noll-Mcclintock, and his veterinary oncologist, Dr. Dorothy Girimonte from Haven Animal Health, turned to FidoCure for help.
Meet Dexter, a lovable mixed-breed pup who’s been on a journey of resilience and love since his cancer diagnosis five years ago. His story, as told by his dedicated pet parent, shows how choosing the right care—and a little extra love—can make all the difference. With the support of FidoCure and his healthcare team, Dexter’s family found new ways to understand his health and keep his tail wagging. In this Q&A, you’ll hear how Dexter’s journey with cancer has brought his family closer than ever, proving that hope and connection go a long way.
In the fight against canine cancer, one of the most powerful tools at medicine’s disposal is data. Data can help describe genomes, uncover patterns in care and outcomes, and map effective drug development methodologies. But historically, collecting and making sense of all this data has been an challenge, bottlenecking advancement. At the intersection of biotechnology, AI, and veterinary medicine, FidoCure is changing this paradigm, leveraging big data and advanced analytics to improve canine cancer treatment to transform our understanding and treatment of cancer in canine companions.
The global veterinary oncology market has been experiencing remarkable growth, reaching a valuation of $259.4B in 2023. This surge reflects a significant shift in how pet parents approach cancer treatment for their beloved companions. Several factors are driving this expansion: increasing pet ownership rates (accelerated by the COVID-19 pandemic), a cultural shift in viewing pets as family members, and advancements in veterinary medicine. As households increasingly view their pets as family members, they're more willing to invest in sophisticated health treatments, including cancer care. This growing market presents both challenges and opportunities for innovative approaches to pet cancer treatment.
We are excited to share that Dr. Lucas Rodrigues, FidoCure's Head of Veterinary Research, will be presenting twice at the 23rd Federation of Asian Veterinary Associations (FAVA) Congress, taking place from October 25 to October 27, 2024. This event marks an important opportunity for us to engage with veterinary professionals from around the world and contribute to the ongoing dialogue about canine cancer treatment.
Gastrointestinal (GI) tumors in dogs are relatively rare but can be serious when they occur. These tumors affect the stomach, intestines, or other parts of the digestive system, and they can include various types such as gastrointestinal carcinomas, gastrointestinal stromal tumors (GIST), and leiomyosarcoma. While these tumors may cause symptoms like vomiting, weight loss, or changes in appetite, their treatment and prognosis depend on the type and stage of the tumor.
PALO ALTO, Calif. (October 15, 2024) — FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings at the 2024 Veterinary Cancer Society (VCS) Annual Conference. This research, Genetic Alterations Associated with Prognosis and Better Therapeutic Outcomes in Dogs with
Splenic Hemangiosarcoma, marks a significant advancement in the fight against hemangiosarcoma, the most prevalent and deadly cancer in dogs. This presentation highlights FidoCure’s work to connect cutting-edge science with one of the most pressing unmet needs in animal health.
